About Oxford Cancer Analytics
Oxford Cancer Analytics is a company based in Oxford (United Kingdom) founded in 2018 by Andreas Halner and Peter Jianrui Liu. Oxford Cancer Analytics has raised $16.47 million across 3 funding rounds from investors including Macmillan Cancer Support, Oxford Technology and MEGAROBO. The company has 7 employees as of February 28, 2021. Oxford Cancer Analytics offers products and services including DEcancer platform. Oxford Cancer Analytics operates in a competitive market with competitors including Oncimmune, Biodesix, OncoCyte, Broncus and Riverain Tech, among others.
- Headquarter Oxford, United Kingdom
- Employees 7 as on 28 Feb, 2021
- Founders Andreas Halner, Peter Jianrui Liu
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oxford Cancer Analytics Ltd
- Date of Incorporation 03 Feb, 2020
- Jurisdiction OXFORD, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.47 M (USD)
in 3 rounds
-
Latest Funding Round
$11 M (USD), Series A
Jan 09, 2025
-
Investors
Macmillan Cancer Support
& 12 more
-
Employee Count
7
as on Feb 28, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Oxford Cancer Analytics
Oxford Cancer Analytics offers a comprehensive portfolio of products and services, including DEcancer platform.
AI-powered platform for detecting cancer biomarkers in blood samples.
Funding Insights of Oxford Cancer Analytics
Oxford Cancer Analytics has successfully raised a total of $16.47M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $11 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Oxford Cancer Analytics
Oxford Cancer Analytics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Macmillan Cancer Support, Oxford Technology and MEGAROBO.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on diagnostics start-ups and digital solutions.
|
Locked | Locked | Locked | |
|
Investments are focused on health technology for global impact.
|
Locked | Locked | Locked | |
|
Venture capital fund focused om consumer tech sector
|
Locked | Locked | Locked |
Investor details for Oxford Cancer Analytics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Oxford Cancer Analytics
Investment portfolio details for Oxford Cancer Analytics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Oxford Cancer Analytics
Detailed financials for Oxford Cancer Analytics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oxford Cancer Analytics Comparisons
Peer comparison for Oxford Cancer Analytics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Oxford Cancer Analytics
Oxford Cancer Analytics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Oncimmune, Biodesix, OncoCyte, Broncus and Riverain Tech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Diagnostics and risk assessment solutions for lung cancer are developed.
|
|
| Locked | Locked | Locked |
Cancer detection diagnostics assays are developed and offered.
|
|
| Locked | Locked | Locked |
Non-invasive diagnostic test solutions for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Minimally invasive technologies for lung disease treatment are developed.
|
|
| Locked | Locked | Locked |
Software tools are developed for early lung disease detection.
|
|
| Locked | Locked | Locked |
AI-based proteomic analysis for oncology therapy planning is offered.
|
Detailed competitors of Oxford Cancer Analytics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oxford Cancer Analytics
Complete news archive for Oxford Cancer Analytics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oxford Cancer Analytics
Oxford Cancer Analytics was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Oxford Cancer Analytics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Peter Jianrui Liu is the current CEO of Oxford Cancer Analytics. They have also founded this company.
Oxford Cancer Analytics is a funded company, having raised a total of $16.47M across 3 funding rounds to date.
As of Feb 28, 2021, the latest employee count at Oxford Cancer Analytics is 7.
Founded in 2018 in Oxford, United Kingdom, Oxford Cancer Analytics operates in the health technology sector. An AI platform named DEcancer is provided for lung cancer detection through liquid biopsy analysis. Blood test results are examined for DNA, protein, and epigenetics markers. The service supports early identification in clinical settings, with focus on non-invasive diagnostics.
Oxford Cancer Analytics offers DEcancer platform.
Oxford Cancer Analytics has 13 investors. Key investors include Macmillan Cancer Support, Oxford Technology, MEGAROBO, Cancer Research UK, and The Francis Crick Institute.